Extracellular vesicle biomarkers for early AD detection

Mechanistically-Specific Hypotheses: EV-Derived Biomarkers for Early/Prodromal AD

Hypothesis 1: Neuron-Derived EV p-tau231 as Ultra-Early Diagnostic Marker

Mechanism

Neuron-derived extracellular vesicles (NDEVs) isolated via L1CAM (CD171) surface capture contain pathologically relevant tau species. Phosphorylation at threonine 231 (p-tau231) occurs upstream of other phosphorylation events in the tau seeding cascade and may reflect early conformational changes in neuronal tau before fibrillization. NDEV p-tau231 likely represents intracellular tau that is actively released via the exosomal pathway during early neurodegenerative priming, before extracellular plaque formation becomes dominant.

Key Evidence

• Winston et al. (2019) demonstrated that NDEV p-tau181 discriminates AD from controls with AUC > 0.90 (PMID: 31278165)
• Other studies show p-tau231 elevation in CSF of preclinical cases

Testable Prediction

If p-tau231 in NDEVs reflects early intraneuronal tau pathology, then longitudinal sampling should show p-tau231 elevation prior to detectable increases in plasma p-tau181 or p-tau217 in cognitively normal individuals who later convert to MCI/AD. This would be tested by comparing baseline NDEV p-tau231 levels between converters vs. non-converters over 3-5 years using ultrasensitive Simoa assay. Falsification: if NDEV p-tau231 does not precede plasma p-tau181 changes, the hypothesis is rejected.

Primary Target

MAPT (tau protein), specifically p-tau231 epitope

Hypothesis 2: Synaptic Vesicle Protein SV2C as Marker of Presynaptic Terminal Vulnerability

Mechanism

Synaptic vesicle protein 2C (SV2C) is selectively enriched in a subset of cortical synapses (particularly cholinergic terminals) and is trafficked into neuronal EVs via AP-2/clathrin-mediated endocytosis followed by intraluminal vesicle formation. Unlike broadly expressed synaptic proteins (SNAP-25, synapsin-1), SV2C's restricted expression pattern may make its EV levels more specific for vulnerable synaptic populations. Reductions in NDEV SV2C may therefore reflect early terminal loss before volumetric changes.

Key Evidence

• Decreased SV2C expression is observed in AD prefrontal cortex (PMID: 27260880)
• EV synaptic protein cargo reflects synaptic activity and turnover rates

Testable Prediction

If SV2C in NDEVs specifically reflects cholinergic terminal integrity, then NDEV SV2C levels should correlate with CSF cholinergic markers (e.g., acetylcholinesterase activity) and show greater deficit than NDEV SNAP-25 in prodromal AD. Falsification: if SV2C levels in NDEVs do not correlate with cholinergic markers or show equivalent decline to other synaptic proteins, the specificity claim is rejected.

Primary Target

SV2C (Synaptic Vesicle Protein 2C)

Hypothesis 3: Microglial EV Cargo TREM2 and Complement C1q as Neuroinflammatory Signatures

Mechanism

Microglia-derived EVs (MDEVs) isolated by CD11b (ITGAM) capture carry complement cascade components and TREM2 that reflect microglial activation state. Complement C1q initiates the classical pathway and opsonizes synapses for phagocytosis—a mechanism implicated in synaptic loss. MDEV C1q elevation in prodromal AD would indicate complement-mediated "synaptic pruning" is actively occurring. TREM2 variants modulate this response; risk variants (R47H) may alter the cargo profile toward a more phagocytic phenotype.

Key Evidence

• TREM2 expression on microglia is elevated in AD and modulates disease progression (PMID: 28120856)
• Complement activation precedes synapse loss in AD models (PMID: 25427974)

Testable Prediction

If MDEV C1q reflects complement-mediated synaptic elimination, then individuals with elevated MDEV C1q will show faster cognitive decline AND greater reduction in NDEV synaptic proteins (from Hypothesis 2), even after controlling for amyloid burden. Falsification: if MDEV C1q levels do not predict synaptic protein decline or cognitive trajectory, the mechanistic link is unsupported.

Primary Target

C1QA/C1QB/C1QC (Complement C1q subcomponents) and TREM2

Hypothesis 4: EV-

Skeptic's Evaluation of EV-Derived Biomarker Hypotheses for Early AD

Hypothesis 1: NDEV p-tau231 as Ultra-Early Diagnostic Marker

Strongest Specific Weakness: Citation Misattribution and Mechanistic Imprecision

The hypothesis claims "Winston et al. (2019) demonstrated that NDEV p-tau181 discriminates AD from controls with AUC > 0.90" as key supporting evidence for p-tau231. This is a conflation of distinct phospho-epitopes. Winston et al. (2019, PMID: 31278165) specifically validated NDEV p-tau181, not p-tau231. The evidentiary foundation for p-tau231 is considerably weaker than presented—you've borrowed the credibility of one epitope to support another without establishing equivalent evidence.

The mechanistic claim that p-tau231 "occurs upstream" in the tau seeding cascade is also imprecise. Phosphorylation at multiple sites (T181, T217, T231, S396) reflects the activity of overlapping kinase families (GSK-3β, CDK5, DYRK1A) acting in parallel on soluble tau, not a strictly sequential cascade. Regional and cellular context matters enormously.

Counter-Evidence and Known Complications

Ultrasensitive plasma p-tau assays now perform exceptionally well in preclinical populations. Janelidze et al. (2020, PMID: 32053791) and Palmqvist et al. (2025) demonstrated plasma p-tau217 AUC > 0.90 for detecting amyloid positivity in cognitively unimpaired individuals. The assumption that plasma assays lack sensitivity in preclinical stages is increasingly obsolete.

L1CAM capture is neither specific nor consistent. L1CAM (CD171) expression is not exclusive to neurons; it appears on some glial populations, and L1CAM+ isolation captures only a subset of neuron-derived EVs. The bead-based capture introduces substantial inter-individual variability in yield (Kanemoto et al., 2016, PMID: 27588270).

The "neurodegenerative priming" concept is vague and potentially unfalsifiable. If a biomarker fails to show early changes, proponents can always argue that "priming" wasn't sufficiently advanced—this framing lacks operational specificity for hypothesis testing.

p-tau231 is elevated in non-AD tauopathies. Frontotemporal lobar degeneration with MAPT mutations and progressive supranuclear palsy also show elevated p-tau231 in CSF, limiting specificity for AD (Schöll et al., 2017, PMID: